HIF1A and neoplasm: In addition, a plausible surrogate biomarker for monitoring the anti-proliferative action of anti-HIF-1 drugs would appear to be 18FDG-PET: since HIF-1 upregulates glycolysis an anti-HIF-1 drug might be expected to inhibit tumour uptake of the glucose analogue 18FDG.